股票 › OCS
奥库利斯制药 OCS
美股市值排名 #3686
$7.49 +$0.66 (+9.66%)
休市 · Nov 6, 8:20 pm ET · 最新盘后价 $7.49 0.00%
开盘$6.83
昨收$6.83
当日区间$6.81 – $7.64
成交量404.1K
市值$463.78M
市盈率（TTM）–
股息率–
OCS 相关新闻
匹配 Oculis 或代码 OCS 的头条新闻，按最新排序。
- Top-performing Hong Kong stocks this week | Lightelligence shares rose more than 21% for the week, with its Scale-up OCS becoming a core growth engine; the company was included in the Stock Connect program this month. Maifeishi gained nearly 21%, upgradin 正面
- Stifel Maintains Oculis(OCS.US) With Buy Rating, Maintains Target Price $40
- Dongtu Technology (300353.SZ): The industrial network communications business segment does not involve OCS optical circuit switching products.
- Material Management Information related to Judgment of Investment ([국책과제 선정]피지컬AI 기반 SW플랫폼 연구개발 생태계 조성사업(협업지능 피지컬AI SW 표준화 및 모듈형 SDF-OCS 설계 구축))
- H.C. Wainwright Maintains Oculis(OCS.US) With Buy Rating, Raises Target Price to $39 正面
- LifeSci Capital Maintains Oculis(OCS.US) With Buy Rating, Maintains Target Price $41
- Needham Maintains Oculis(OCS.US) With Buy Rating, Maintains Target Price $38
- LifeSci Capital Maintains Oculis(OCS.US) With Buy Rating, Cuts Target Price to $41 负面
- Guggenheim Maintains Oculis(OCS.US) With Buy Rating, Maintains Target Price $45
- LifeSci Capital Maintains Oculis(OCS.US) With Buy Rating, Maintains Target Price $45
- TransMedics (TMDX): Buy Rating Backed by Accelerating U.S. Organ Transplant Volumes and Expanding OCS Utilization
- H.C. Wainwright Maintains Oculis(OCS.US) With Buy Rating, Maintains Target Price $26
- J.P. Morgan Maintains Oculis(OCS.US) With Buy Rating, Cuts Target Price to $20 负面
- J.P. Morgan Gives a Buy Rating to Oculis Holding (OCS)
- Analysts Have Conflicting Sentiments on These Healthcare Companies: Oculis Holding (OCS), Stevanato Group (STVN) and Structure Therapeutics, Inc. Sponsored ADR (GPCR)
暂无评论——快来第一个聊聊 OCS。
登录后参与讨论。